Kaisa Group Holdings has entered an agreement to purchase 18.57% stake in Zhenxing Biopharmaceutical & Chemical.

Based in China, the acquirer company is involved in property investment, development, and management businesses. It aims to expand its footprint in the healthcare industry through the acquisition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

“Zhongyuan Union Cell & Gene Engineering, formerly Zhongyuan Union Stem Cell Bioengineering, plans to divest 67% share in a pharmaceutical tech company headquartered in Zhejiang.”

The purchase consideration for the acquisition is agreed to be $331.65m.

Zhongyuan Union Cell & Gene Engineering, formerly Zhongyuan Union Stem Cell Bioengineering, plans to divest 67% share in a pharmaceutical tech company headquartered in Zhejiang.

The divestment is expected to generate CNY60m ($9.1m) in proceeds for Zhongyuan.

Zhongyuan Union Stem Cell Bioengineering is a biotechnology company based in China.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now